Sepracor Inc. is a research-based pharmaceutical company dedicated to treating and preventing human disease by discovering, developing, and commercializing innovative pharmaceutical products that are directed toward serving unmet medical needs. Our drug development program has yielded a portfolio of pharmaceutical products and candidates with a focus on the treatment of respiratory and central nervous system disorders. Our commercialization efforts are carried out by our U.S.-based primary care and specialty-oriented sales force, as well as through out-licensing partnerships.

We currently commercialize four proprietary products in the U.S.: LUNESTA^® (eszopiclone); XOPENEX HFA^® (levalbuterol tartrate) Inhalation Aerosol, a hydrofluoroalkane (HFA) metered-dose inhaler (MDI); XOPENEX^® (levalbuterol HCl) Inhalation Solution; and BROVANA^® (arformoterol tartrate) Inhalation Solution.

In January 2008, we entered into a development, marketing and commercialization agreement with Nycomed for ciclesonide in the U.S. Ciclesonide is the active ingredient in Nycomed's ALVESCO^® HFA Inhalation Aerosol for asthma and OMNARIS™ AQ Nasal Spray for allergic rhinitis. ALVESCO HFA and OMNARIS AQ are approved by the United States (U.S.) Food and Drug Administration (FDA) and we expect to commercially launch OMNARIS AQ in April 2008 and plan to launch ALVESCO HFA during the second half of 2008.

In late 2007, we licensed a product candidate, BIA 2-093 for the treatment of epilepsy, from Bial Portela & Company S.A., a Portuguese pharmaceutical company. Bial has conducted Phase III Studies of BIA 2-093. Under the agreement, Sepracor is responsible for preparation of a New Drug Application (NDA) and submission of the NDA to the FDA. Contingent on approval from the FDA, Sepracor expects to market this product candidate to neurologists and epileptologists in the U.S.

Sepracor has also engaged in out-licensing agreements that include: Schering-Plough for CLARINEX^® (desloratadine); sanofi-aventis for ALLEGRA^® (fexofenadine HCl); and UCB Pharma for XYZAL^® /XUSAL™ (levocetirizine).

Sepracor is also pursuing expansion of the LUNESTA franchise beyond the U.S. and in the second half of 2007, entered into an agreement with Eisai Co. Ltd. for development and commercialization of eszopiclone in Japan. In September 2007, we entered into an alliance with GlaxoSmithKline for international (excluding the U.S., Canada, Japan and Mexico) commercialization of eszopiclone under the brand name LUNIVIA^®.

We continue to broaden our research and development efforts beyond development of our currently marketed products. The focus of our discovery efforts is to identify additional drug candidates that are directed toward treating respiratory and central nervous system disorders. These compounds are expected to complement our current pharmaceutical pipeline.

Our corporate headquarters are located in Marlborough, Massachusetts.